Efficacy of Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf)

The efficacy of Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) was studied in FeDeriCa, an open-label, multicenter, randomized trial that enrolled 500 participants with operable or locally advanced HER2-positive breast cancer. The patients were randomized to receive neoadjuvant chemotherapy, a fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase, or intravenous pertuzumab and trastuzumab during neoadjuvant and adjuvant treatment.

The primary endpoint of the FeDeriCa trial was non-inferiority in pertuzumab serum trough concentrations at cycle 7, comparing fixed-dose Phesgo with intravenous pertuzumab. Secondary endpoints included trastuzumab serum trough concentrations at cycle 7, pathological complete response (pCR) and safety. The fixed-dose combination Phesgo demonstrated noninferiority in serum trough concentrations of Pertuzumab/trastuzumab compared with intravenous pertuzumab and trastuzumab. The pCR rate of the Phesgo group was 59.7%, and the pCR rate of the intravenous pertuzumab/trastuzumab group was 59.5%. The safety profile of Phesgo was comparable to intravenous pertuzumab/trastuzumab, except for an increase in dosing-related reactions.

The original Phesgo drug is not marketed in the country and therefore cannot be included in medical insurance. Since Phesgo's original drug has been on the market overseas for a short time, there is less price and other related information. For specific prices and drug information, please consult Yaode's medical consultant.